The CRISPR-Cas9 Patent Appeal: Where Do We Go From Here?

Research output: Contribution to journalArticlepeer-review


An appellate court in the United States affirmed the Patent Office's finding that the Broad Institute's patents covering eukaryotic applications of CRISPR-Cas9 was separately patentable over the University of California's (UC) earlier patent application. This does not bode well for future negotiations between UC and the Broad Institute, even as nuclease technology continues to eclipse the original dispute. This perspective explores the appellate decision, where UC goes from here, and what this all means for scientists in the future.
Original languageEnglish (US)
Pages (from-to)309-311
JournalCRISPR Journal
Issue number5
StatePublished - Oct 1 2018
Externally publishedYes


Dive into the research topics of 'The CRISPR-Cas9 Patent Appeal: Where Do We Go From Here?'. Together they form a unique fingerprint.

Cite this